Literature DB >> 21437583

Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran.

Amin Talebi Bezmin Abadi1, Ali Ghasemzadeh, Tarang Taghvaei, Ashraf Mohabbati Mobarez.   

Abstract

The increase in the prevalence of antibiotic resistance in Helicobacter pylori had a drastic effect on successful treatment. Up-to-date information on H. pylori antibiotic therapy in Iran is still limited. In this study, we aim to determine the prevalence of antibiotic resistance among the H. pylori strains. Furthermore, the possibility of using fluoroquinolones for antibiotic treatment was investigated. Antral biopsy specimens obtained from dyspeptic patients were investigated for H. pylori. Bacterial culture and susceptibility tests were done based on standard methods. H. pylori ATCC 43504 was used as a quality control. In the current study, 30 H. pylori strains were selected randomly and retested to confirm our susceptibility tests. Of 170 patients, 150 were identified as positive for H. pylori (88.2%). In this study, 150 single colonies of H. pylori strains [81 women (54%), 69 men (46%); mean age 38.6; aged 21-70 years] were collected. Primary resistance of H. pylori isolates were clarithromycin (34%), metronidazole (78.6%), tetracycline (9.3%), amoxicillin (10%), levofloxacin (5.3%) and moxifloxacine (4.6%). In conclusion, our results show that we are confronting a new generation of resistant strains of H. pylori in Iran. This alarming finding indicates an urgent need for introduction of new effective antibiotics in our country. Since the majority of clinicians prefer to continue with the ineffective antibiotics as therapeutic regimens, they must also be prepared to deal with treatment failures.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21437583     DOI: 10.1007/s11739-011-0563-1

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  33 in total

1.  Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe.

Authors:  S Koletzko; F Richy; P Bontems; J Crone; N Kalach; M L Monteiro; F Gottrand; D Celinska-Cedro; E Roma-Giannikou; G Orderda; S Kolacek; P Urruzuno; M J Martínez-Gómez; T Casswall; M Ashorn; H Bodanszky; F Mégraud
Journal:  Gut       Date:  2006-04-07       Impact factor: 23.059

2.  Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication.

Authors:  H Fakheri; S Merat; V Hosseini; R Malekzadeh
Journal:  Aliment Pharmacol Ther       Date:  2004-01-01       Impact factor: 8.171

3.  Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt.

Authors:  May Sherif; Zaynab Mohran; Hanan Fathy; David M Rockabrand; Patrick J Rozmajzl; Robert W Frenck
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 4.  Gastric cancer in Iran: epidemiology and risk factors.

Authors:  Reza Malekzadeh; Mohammad H Derakhshan; Zinab Malekzadeh
Journal:  Arch Iran Med       Date:  2009-11       Impact factor: 1.354

5.  Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.

Authors:  Richard J Saad; Philip Schoenfeld; Hyungjin Myra Kim; William D Chey
Journal:  Am J Gastroenterol       Date:  2006-03       Impact factor: 10.864

6.  The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy.

Authors:  Naser Ebrahimi-Dariani; Shahram Mirmomen; Fariborz Mansour-Ghanaei; Pedram Noormohammadpoor; Rasoul Sotodehmanesh; Bahram Haghpanah; Hossein Bahrami
Journal:  Med Sci Monit       Date:  2003-08

7.  High prevalence of virulent Helicobacter pylori strains in symptomatic Bulgarian patients.

Authors:  Lyudmila Boyanova; Rumiana Markovska; Daniel Yordanov; Maya Marina; Katusha Ivanova; Stephan Panayotov; Galina Gergova; Ivan Mitov
Journal:  Diagn Microbiol Infect Dis       Date:  2009-08       Impact factor: 2.803

8.  Helicobacter pylori cagA status and peptic ulcer disease in Iran.

Authors:  Zivar Salehi; Mohammad Halimi Jelodar; Mehdi Rassa; Moheb Ahaki; Hamidreza Mollasalehi; Farhad Mashayekhi
Journal:  Dig Dis Sci       Date:  2008-07-10       Impact factor: 3.199

9.  dupA as a risk determinant in Helicobacter pylori infection.

Authors:  Masoumeh Douraghi; Marjan Mohammadi; Akbar Oghalaie; Afshin Abdirad; Mohammad Ali Mohagheghi; Mahmoud Eshagh Hosseini; Hojat Zeraati; Amir Ghasemi; Maryam Esmaieli; Nazanin Mohajerani
Journal:  J Med Microbiol       Date:  2008-05       Impact factor: 2.472

10.  Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods.

Authors:  Lyudmila Boyanova; Galina Gergova; Rossen Nikolov; Lubomir Davidkov; Victor Kamburov; Christo Jelev; Ivan Mitov
Journal:  Diagn Microbiol Infect Dis       Date:  2008-01-14       Impact factor: 2.803

View more
  16 in total

Review 1.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

2.  Prevalence of horB gene among the Helicobacter pylori strains isolated from dyspeptic patients: first report from Iran.

Authors:  Tarang Taghvaei; Amin Talebi Bezmin Abadi; Ali Ghasemzadeh; Behnam Kalali Naderi; Ashraf Mohabbati Mobarez
Journal:  Intern Emerg Med       Date:  2011-05-11       Impact factor: 3.397

Review 3.  Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review.

Authors:  Reza Ghotaslou; Hamed Ebrahimzadeh Leylabadlo; Yalda Mohammadzadeh Asl
Journal:  World J Methodol       Date:  2015-09-26

4.  Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland.

Authors:  Elżbieta Karczewska; Karolina Klesiewicz; Iwona Skiba; Izabela Wojtas-Bonior; Edward Sito; Krzysztof Czajecki; Małgorzata Zwolińska-Wcisło; Alicja Budak
Journal:  Gastroenterol Res Pract       Date:  2012-05-27       Impact factor: 2.260

Review 5.  Helicobacter pylori in Iran: A systematic review on the antibiotic resistance.

Authors:  Farzad Khademi; Farkhondeh Poursina; Elham Hosseini; Mojtaba Akbari; Hajieh Ghasemian Safaei
Journal:  Iran J Basic Med Sci       Date:  2015-01       Impact factor: 2.699

6.  Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial.

Authors:  Mohsen Masoodi; Mahshid Talebi-Taher; Khadijeh Tabatabaie; Siamak Khaleghi; Amir-Hossein Faghihi; Shahram Agah; Reyhaneh Asadi
Journal:  Middle East J Dig Dis       Date:  2015-04

Review 7.  Novel Idea: Virulence-Based Therapy Against Helicobacter pylori Infection (Smart Therapy).

Authors:  Amin Talebi Bezmin Abadi
Journal:  Front Med (Lausanne)       Date:  2014-06-23

8.  Multicenter Study of Antibiotic Resistance Profile of H. pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China.

Authors:  Ran Han; Hong Lu; Ming-Wan Jiang; Ke-Wen Tan; Zhong Peng; Jia-Li Hu; Dian-Chun Fang; Chun-Hui Lan; Xiao-Ling Wu
Journal:  Gastroenterol Res Pract       Date:  2016-05-09       Impact factor: 2.260

Review 9.  Therapy of Helicobacter pylori: present medley and future prospective.

Authors:  Amin Talebi Bezmin Abadi
Journal:  Biomed Res Int       Date:  2014-04-01       Impact factor: 3.411

10.  Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials.

Authors:  Musthafa Chalikandy Peedikayil; Fahad Ibrahim Alsohaibani; Abdullah Hamad Alkhenizan
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.